Patients' perceptions and experiences of familial hypercholesterolemia, cascade genetic screening and treatment

Sarah J Hardcastle1, Ellen Legge, Chris S Laundy

  • 1School of Sport and Service Management, University of Brighton, Denton Road, Eastbourne, East Sussex, BN20 7SP, UK.

Insights

Familial hypercholesterolemia (FH) is a genetic disorder increasing heart disease risk. Patients perceive medication as sufficient, leading to low screening adherence among relatives, necessitating professional-led recruitment for better cascade screening outcomes.

Area of Science:

  • Genetics
  • Cardiology
  • Public Health

Background:

  • Familial hypercholesterolemia (FH) is a prevalent genetic disorder impacting 1 in 300-500 individuals.
  • It is characterized by elevated LDL cholesterol, significantly increasing the risk of early-onset coronary heart disease (CHD) and premature mortality.
  • Untreated FH poses a >50% CHD risk for men by age 50 and a 30% risk for women by age 60.

Purpose of the Study:

  • To explore the perceptions and experiences of FH patients undergoing genetic cascade screening.
  • To understand factors influencing adherence to health-protective behaviors and perceptions of genetic screening in FH.
  • To address the low detection rate of FH despite effective management options.

Main Methods:

  • Face-to-face interviews were conducted with 18 FH patients.
  • Assessed patient knowledge and understanding of FH.
  • Explored adherence to health behaviors and perceptions of genetic screening.

Main Results:

  • Participants recognized FH as a serious genetic condition with risks of CHD and premature death.
  • Many underestimated FH severity and lifestyle changes, relying on medication.
  • Relatives were reluctant to screen due to fatalism or low motivation, with patients lacking influence for recruitment.
  • Patients desired greater hospital support for contacting relatives.

Conclusions:

  • Direct recruitment by medical professionals is recommended for cascade screening, leveraging their perceived authority.
  • Clinicians must provide clear information on FH seriousness and adherence to medication and lifestyle changes, especially for asymptomatic individuals.
Abstract

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
805
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
563
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
611